Click Here to Go Directly to the Story




U.S. EDITION
Full Table of Contents
Cover Story
Special Report
Up Front
Readers Report
Corrections & Clarifications
Books
Technology & You
Economic Viewpoint
Business Outlook
News: Analysis & Commentary

In Business This Week
Washington Outlook
International Business
International Outlook
Government
Legal Affairs
Finance
Working Life
Social Issues
Developments to Watch

Science & Technology
The Corporation
Management
BusinessWeek Investor
Dividends
The Barker Portfolio
Inside Wall Street
Figures of the Week
Editorials


INTERNATIONAL EDITIONS
International -- Asian Cover Story
International -- European Cover Story
International -- Readers Report
International -- Asian Business
International -- European Business
International -- Finance
International -- Int'l Figures of the Week




JANUARY 27, 2003

Corrections & Clarifications


  STORY TOOLS
Printer-Friendly Version
E-Mail This Story

On This Page
"Professional services: The help needs help" (Industry Outlook 2003, Jan. 13, 2003)

"Brainwork from the experts" ("Where to invest" Dec. 30, 2002/Jan. 6, 2003)

"Stem-cell setback" (Capital Wrapup, Jan. 13, 2003)


"Professional services: The help needs help" (Industry Outlook 2003, Jan. 13, 2003)

"Professional services: The help needs help" (Industry Outlook 2003, Jan. 13) incorrectly stated that Arthur D. Little closed its doors in 2002. The firm declared bankruptcy and was sold to another company, but it continues in operation.

Back to Top

"Brainwork from the experts" ("Where to invest" Dec. 30, 2002/Jan. 6, 2003)

"Brainwork from the experts" ("Where to invest," Dec. 30/Jan. 6) overstated the loss to an investor holding a 10-year U.S. Treasury note with a 4% coupon over one year in which market yields rise to 5%. The loss, after interest payments, would be approximately 3.15%, not 25%.

Back to Top

"Stem-cell setback" (Capital Wrapup, Jan. 13, 2003)

"Stem-cell setback" (Capital Wrapup, Jan. 13) incorrectly reported that the biotech industry had financed a "multimillion-dollar" campaign to allow continued research on stem cells. Biotech and patients'-rights groups say they have spent tens of thousands of dollars at most on such lobbying.



Back to Top


TODAY'S MOST POPULAR STORIES

  1. India's Economy Hits the Wall
  2. Viacom vs. YouTube: Beyond Privacy
  3. Choosing Where to Grow Old
  4. China: An Olympic Loss for Industry
  5. Wal-Mart Gets a Facelift

Get Free RSS Feed >>
  MARKET INFO
DJIA 11288.54 0.00
S&P 500 1262.9 0.00
Nasdaq 2245.38 0.00

Portfolio Service Update

Stock Lookup

Enter name or ticker



Media Kit | Special Sections | MarketPlace | Knowledge Centers
McGraw-Hill Cos.